Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;11(1):122-8.
doi: 10.1097/COH.0000000000000219.

The promise and pitfalls of long-acting injectable agents for HIV prevention

Raphael J Landovitz  1 , Ryan Kofron, Marybeth McCauley
Affiliations
Review

The promise and pitfalls of long-acting injectable agents for HIV prevention

Raphael J Landovitz et al. Curr Opin HIV AIDS. 2016 Jan.

Abstract

Purpose of review: Preexposure prophylaxis for HIV prevention is highly effective when taken as prescribed. Adherence to required dosing regimens for protection may pose challenges. Long-acting agents for HIV prevention may have the potential to improve adherence via favorable pharmacokinetics supportive of infrequent dosing. This review focuses on the potential benefits and considerations for the study and use of 2 long-acting injectable agents, cabotegravir (GSK1265744LA, CAB LA) and rilpivirine (TMC278LA, RPV LA), for use as chemoprophylaxis for HIV prevention.

Recent findings: Oral RPV is United States Food and Drug Administration approved for HIV treatment (in combination with other antiretrovirals). Both CAB LA and RPV LA are currently in phase 2a safety/tolerability/pharmacokinetic studies in anticipation and support of future efficacy evaluation. Both agents have favorable pharmacokinetics, and use is complicated by injection site reactions.

Summary: Long-acting injectable formulations, if safe and well tolerated, may improve pharmacokinetic coverage of exposures to HIV infection. Complexities around safety, tolerability, and starting/stopping protocols require careful consideration.

PubMed Disclaimer

References

    1. Grant R, Lama J, Anderson P, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599. - PMC - PubMed
    1. Grant R, Anderson P, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet. 2014;14:820–829. - PMC - PubMed
    1. Molina J, Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: Results of the ANSR Ipergay trial [Abstract 23LB]. 22nd Conference on Retroviruses and Opportunistic Infections (CROI); 23–26 February 2015; Seattle, Washington.
    1. McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: The PROUD study [Abstract 22LB]. 22nd Conference on Retroviruses and Opportunistic Infections (CROI); 23–26 February 2015; Seattle, Washington.
    1. Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410. - PMC - PubMed

Publication types

MeSH terms